Syros Pharmaceuticals and Incyte agreed to work together on the development of potential drugs to treat patients with myeloproliferative neoplasms. Under the terms of the deal, Syros will receive $20 million upfront and Incyte will have the option to obtain exclusive rights for therapies modulating up to seven validated targets discovered during the collaboration.
Syros partners with Incyte on rare bone marrow disorder drug studies
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.